2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1904

IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients
Abstract Number: 1905

Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR)
Abstract Number: 1906

Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)
Abstract Number: 1907

Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial
Abstract Number: 1908

Preliminary Identification of Arthritis-Associated Microbiota in Experimental Spondyloarthritis
Abstract Number: 1909

miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Abstract Number: 1910

Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow
Abstract Number: 1911

Targeting the Oxidative Stress Pathway in Experimental Spondyloarthritis Reduces Pro-inflammatory Response in Rat Macrophages and Modulates Their Metabolic Requirements
Abstract Number: 1912

High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis
Abstract Number: 1913

Associations of HLA-B Alleles, Enthesitis and Peripheral Arthritis in Ankylosing Spondylitis
Abstract Number: 1914

Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Abstract Number: 1915

Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis
Abstract Number: 1916

Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis
Abstract Number: 1917

Tubulointerstitial Inflammation Predicts Outcomes in Lupus Nephritis
Abstract Number: 1918

Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].